Abstract
Over 90% of patients with acute promyelocytic leukemia (APL) harbor the typical translocation characterized by the dual fusion of
PML::RARA
and
RARA::PML
transcripts. Here, we report a case with a single fusion of
PML::RARA
formed on der(17), without the
RARA::PML
fusion, and the patient responded well to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) therapy. To our knowledge, this represents only the fourth reported case of this type. Our findings indicate that the
PML::RARA
fusion is the primary driver of APL leukemogenesis and the main therapeutic target for ATRA and ATO, suggesting that the
RARA::PML
transcript may not be essential for APL development.